Johnson&Johnson VISION
  • VERITAS™ Vision System is a recently launched next-generation phacoemulsification (phaco) system designed to address three critical areas: patient safety, surgeon efficiency and comfort
  • More than 40 abstracts will be presented across a range of Johnson & Johnson Vision products including: TECNIS Synergy® IOL, TECNIS Eyhance® IOL and VERITAS™ Vision System

Amsterdam, The Netherlands (4 October 2021) – Johnson & Johnson Vision*, a global leader in eye health and part of the Johnson & Johnson Medical Devices Companies**, will showcase the new VERITAS™ Vision System and a range of clinical data relating to their products at the upcoming European Society of Cataract and Refractive Surgeons (ESCRS) 2021 Annual Meeting, 8-11 October.

VERITAS™ Vision System is a next-generation phacoemulsification (phaco) system designed to address three critical areas: patient safety, surgeon efficiency and comfort. It features several innovations to provide a better surgical experience and is now available to experience in person for the first time in Europe at the Johnson & Johnson ESCRS Booth (#B14). 

In addition, 29 scientific communications from both Johnson & Johnson Vision sponsored studies and investigator-initiated studies (IIS) will be presented, including TECNIS Synergy® IOL, TECNIS Eyhance® IOL and TECNIS® Toric II IOL (a next-generation monofocal IOL launched earlier this year). Data presented at ESCRS will show excellent visual performance and rotational stability across the TECNIS® IOL portfolio1-4

“It’s been another fantastic year for Johnson and Johnson Vision,” said Warren Foust, Worldwide President, Surgical at Johnson & Johnson Vision. “Not only are we celebrating 20 years of TECNIS® but we’ve also just launched our VERITAS™ Vision System, which is now available in Europe. The VERITAS™ Vision System is designed to give better fluidics and increased chamber stability, and has had excellent feedback from the clinical community. Do come and speak to us at ESCRS to find out more.”

“I’m so excited to be meeting our customers face-to-face at this year’s ESCRS,” said Erin McEachren, Regional Vice President, Europe, Middle East & Africa, Johnson & Johnson Surgical Vision. “In addition to the wealth of data being presented around our products, it is great to be showcasing new innovations like the TECNIS® Toric II platform and VERITAS™ Vision System. I’m pleased to announce as well that you’ll be able to experience the VERITAS™ Swivel Handpiece at our ESCRS Booth, which puts ease of maneuverability and comfort in the hands of ophthalmologists5.”

Key scientific abstracts related to Johnson & Johnson Vision at ESCRS 2021 (a complete listing is available at include the following: 


  • Clinical evaluation of a diffractive continuous-range-of-vision intraocular lens with the Salzburg Reading Desk 
  • Functional outcomes after binocular implantation of a continuous-range-of-vision IOL in refractive lens exchange patients 
  • Long term non-randomized results with a new continuous-range-of-vision PCIOL
  • Visual outcomes in patients implanted with a new diffractive presbyopia-correcting intraocular lens 
  • Low light visual outcomes and satisfaction in patients implanted with a new diffractive presbyopia-correcting intraocular lens (TECNIS Synergy® IOL vs AcrySof® IQ PanOptix® IOL)

TECNIS Eyhance® and TECNIS® Toric II IOLs

  • Comparative analysis of the visual performance achieved after cataract surgery with implantation of a standard monofocal or a monofocal intraocular lens with modified optical profile: a randomized clinical trial (TECNIS Eyhance® IOL vs VivinexTM ) 
  • Visual acuity, wavefront aberration and defocus curves with enhanced monofocal and monofocal aspheric intraocular lens: A prospective, randomized study (TECNIS Eyhance® IOL vs RayOne Aspheric )
  • Rotational stability, visual performance, and surgeon satisfaction of TECNIS® Toric II IOL (Model ZCU) intraocular lens 

VERITAS™ Vision System 

  • Performance of a new dual mode phacoemulsification system

TearScience® LipiFlow® Thermal Pulsation System

  • Long-term evaluation of thermal pulsation system (LipiFlow®) treatment for ocular surface disease due to meibomian gland dysfunction under two different controlled environments

Educational and interactive sessions

Johnson & Johnson Vision is also hosting (and supporting through educational grants) a series of educational and interactive sessions aimed at sparking conversation and providing an opportunity to share, discuss and learn from leading experts in the field of ophthalmology. These include:  

  • ESCRS Phaco Complex Cases Symposium – Keys for Addressing Complex Cataract Cases with the Latest Phacoemulsification Techniques and Technologies. RAI Amsterdam. Auditorium. 8 October 2021, 12:00 – 13:00 hrs
    • Chairperson Filomena Ribeiro (Portugal) Speaker: Daniel Elies (Spain), Nic Reus (Netherlands), Sri Ganesh (India)
  • EuroTimes Satellite Symposium – “The Refractive Cataract Patient” RAI Amsterdam. Hall 13/Elicium Ballroom, 9 October 2021, 11:45 – 12:30 hrs
    • Chairperson: Prof. Burkhard Dick (GER) / Speakers: Dr Frank Kerkhoff (Netherlands), Prof. Nikica Gabric (Croatia) 
  • EuroTimes Satellite Symposium – “Next level cataract surgery: Innovations for enhancing outcomes, ease and control” RAI Amsterdam. Hall 13/Elicium Ballroom, 10 October 2021,   11:45 – 12:30 hrs 
    • Chairperson: Oliver Findl (Austria) / Speakers: Mayank Nanavaty (UK), Nic Reus (Netherlands), Daniel Elies (Spain) 
  • ESCRS Refractive IOL Symposium – “Optimizing Presbyopia Correction & Astigmatism Management with Modern Lens Technologies” RAI Amsterdam. Hall 9, 10 October 2021,   15:15 – 16:30 hrs. Independent Education Grant Supporters: Johnson & Johnson, Alcon
    • Chairperson: Rudy Nuijts (Netherlands) / Speakers: Filomena Ribeiro (Portugal), Francesco Carones (Italy), Gerd Auffarth (Germany), Oliver Findl (Austria), Thomas Kohnen (Germany)


About Johnson & Johnson Vision*
At Johnson & Johnson Vision*, part of Johnson & Johnson Medical Devices Companies, we have a bold ambition: to change the trajectory of eye health worldwide. Through our operating companies, we deliver innovation that enables eye care professionals to create better outcomes for patients throughout their lives, with products and technologies that address unmet needs including refractive error, cataracts, and dry eye. In communities with greatest need, we work in collaboration to expand access to quality eye care, and we are committed to helping people see better, connect better, live better. Visit us at, follow @JNJVision on Twitter, Johnson & Johnson Vision on LinkedIn, and @JNJVision on Facebook

About Johnson & Johnson Medical Devices Companies**
At Johnson & Johnson Medical Devices Companies, we are helping people live their best lives. Building on more than a century of expertise, we tackle pressing healthcare challenges, and take bold steps that lead to new standards of care while improving people’s healthcare experiences. In surgery, orthopaedics, vision, and interventional solutions, we are helping to save lives and paving the way to a healthier future for everyone, everywhere.

For Healthcare Professionals Only. 

Please reference the Instructions for Use for a complete list of Indications and Important Safety Information and contact our specialists in case of any questions.

©Johnson & Johnson Vision Care Inc., 2021. All rights reserved.

*Johnson & Johnson Vision represents the products and services of Johnson & Johnson Surgical Vision, Inc., Johnson & Johnson Vision Care, Inc., and the affiliates of both.
**The Johnson & Johnson Medical Devices Companies comprise the surgery, orthopedics, vision, and interventional solutions businesses within Johnson & Johnson’s Medical Devices segment

1. DOF2021CT4012 – Steele Study – Clinical Investigation of Rotational Stability of the TECNIS® Toric II Intraocular Lens. 24 April 2021.
2. DOF2020CT4014 – Forte-1 Study – A Comparative Clinical Evaluation of a New TECNIS® Presbyopia Correcting Intraocular Lens Against a PanOptix® Intraocular Lens – DEFOCUS CURVES AND VISUAL ACUITY RESULTS. 19 November 2020.
3. DOF2020CT4015 – Forte-1 Study – A Comparative Clinical Evaluation of a New TECNIS® Presbyopia Correcting Intraocular Lens Against a PanOptix® Intraocular Lens – SPECTACLE WEAR AND SATISFACTION RESULTS. 26 January 2021.
4. DOF2018CT4015 - Clinical Investigation of the TECNIS Eyhance® IOL, Model ICB00 – 6-Month Clinical Study. September 2018.
5. VERITAS™ Claims Matrix. PP2021CT4706.